State-of-the-art combination therapy in 1999

Research output: Contribution to journalArticle

Abstract

Over the past 5 years, the shift in the paradigm of treatment for rheumatoid arthritis involves increasing emphasis on combination therapy. Because rheumatoid arthritis is a lifelong disease process, the results of longer-term studies are essential for ultimately defining the most effective therapies. Differences in drug doses and dose escalation, patient populations, and trial design can make comparisons among currently available studies difficult, particularly those involving combination therapy. In a 2- year study triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine was shown to be superior to single-drug therapy with methotrexate 17.5 mg/week. Another study showed that patients treated with prednisolone, sulfasalazine, and methotrexate responded better than patients treated with sulfasalazine alone, even when the prednisolone and methotrexate doses were tapered. Because of the potential for genetic variations to cause differing responses to drugs, pharmacogenetics may be used in the future to select patients for different therapies.

Original languageEnglish (US)
JournalAmerican Journal of Managed Care
Volume5
Issue number8 SUPPL.
StatePublished - Jun 1 1999

Fingerprint

Art Therapy
Methotrexate
Sulfasalazine
Prednisolone
drug
Rheumatoid Arthritis
Therapeutics
Hydroxychloroquine
Pharmacogenetics
escalation
Pharmaceutical Preparations
paradigm
Disease
Drug Therapy
cause
Population

ASJC Scopus subject areas

  • Nursing(all)
  • Medicine(all)
  • Health(social science)
  • Health Professions(all)

Cite this

State-of-the-art combination therapy in 1999. / O'Dell, James Robert.

In: American Journal of Managed Care, Vol. 5, No. 8 SUPPL., 01.06.1999.

Research output: Contribution to journalArticle

@article{0d9195ceb9574398aa8bc39465364e7c,
title = "State-of-the-art combination therapy in 1999",
abstract = "Over the past 5 years, the shift in the paradigm of treatment for rheumatoid arthritis involves increasing emphasis on combination therapy. Because rheumatoid arthritis is a lifelong disease process, the results of longer-term studies are essential for ultimately defining the most effective therapies. Differences in drug doses and dose escalation, patient populations, and trial design can make comparisons among currently available studies difficult, particularly those involving combination therapy. In a 2- year study triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine was shown to be superior to single-drug therapy with methotrexate 17.5 mg/week. Another study showed that patients treated with prednisolone, sulfasalazine, and methotrexate responded better than patients treated with sulfasalazine alone, even when the prednisolone and methotrexate doses were tapered. Because of the potential for genetic variations to cause differing responses to drugs, pharmacogenetics may be used in the future to select patients for different therapies.",
author = "O'Dell, {James Robert}",
year = "1999",
month = "6",
day = "1",
language = "English (US)",
volume = "5",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "8 SUPPL.",

}

TY - JOUR

T1 - State-of-the-art combination therapy in 1999

AU - O'Dell, James Robert

PY - 1999/6/1

Y1 - 1999/6/1

N2 - Over the past 5 years, the shift in the paradigm of treatment for rheumatoid arthritis involves increasing emphasis on combination therapy. Because rheumatoid arthritis is a lifelong disease process, the results of longer-term studies are essential for ultimately defining the most effective therapies. Differences in drug doses and dose escalation, patient populations, and trial design can make comparisons among currently available studies difficult, particularly those involving combination therapy. In a 2- year study triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine was shown to be superior to single-drug therapy with methotrexate 17.5 mg/week. Another study showed that patients treated with prednisolone, sulfasalazine, and methotrexate responded better than patients treated with sulfasalazine alone, even when the prednisolone and methotrexate doses were tapered. Because of the potential for genetic variations to cause differing responses to drugs, pharmacogenetics may be used in the future to select patients for different therapies.

AB - Over the past 5 years, the shift in the paradigm of treatment for rheumatoid arthritis involves increasing emphasis on combination therapy. Because rheumatoid arthritis is a lifelong disease process, the results of longer-term studies are essential for ultimately defining the most effective therapies. Differences in drug doses and dose escalation, patient populations, and trial design can make comparisons among currently available studies difficult, particularly those involving combination therapy. In a 2- year study triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine was shown to be superior to single-drug therapy with methotrexate 17.5 mg/week. Another study showed that patients treated with prednisolone, sulfasalazine, and methotrexate responded better than patients treated with sulfasalazine alone, even when the prednisolone and methotrexate doses were tapered. Because of the potential for genetic variations to cause differing responses to drugs, pharmacogenetics may be used in the future to select patients for different therapies.

UR - http://www.scopus.com/inward/record.url?scp=0033603285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033603285&partnerID=8YFLogxK

M3 - Article

VL - 5

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 8 SUPPL.

ER -